Guardant Health Inc (NASDAQ:GH) — Market Cap & Net Worth
Market Cap & Net Worth: Guardant Health Inc (GH)
Guardant Health Inc (NASDAQ:GH) has a market capitalization of $12.69 Billion ($12.69 Billion) as of June 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #1881 globally and #700 in its home market, demonstrating a 1.96% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Guardant Health Inc's stock price $127.34 by its total outstanding shares 132599929 (132.60 Million). Review Guardant Health Inc (GH) financial obligations to assess the company's total debt and financial obligations.
Guardant Health Inc Market Cap History: 2018 to 2026
Guardant Health Inc's market capitalization history from 2018 to 2026. Data shows growth from $4.98 Billion to $16.89 Billion (19.54% CAGR).
Index Memberships
Guardant Health Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.43 Trillion | 0.52% | #33 of 976 |
|
NASDAQ Composite
IXIC
|
$41.27 Trillion | 0.03% | #215 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.70 Trillion | 0.75% | #25 of 263 |
Weight: Guardant Health Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Guardant Health Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Guardant Health Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
13.79x
Guardant Health Inc's market cap is 13.79 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $4.98 Billion | $90.64 Million | -$85.06 Million | 54.99x | N/A |
| 2019 | $10.36 Billion | $214.38 Million | -$75.65 Million | 48.33x | N/A |
| 2020 | $17.09 Billion | $286.73 Million | -$253.78 Million | 59.60x | N/A |
| 2021 | $13.26 Billion | $373.65 Million | -$405.67 Million | 35.49x | N/A |
| 2022 | $3.61 Billion | $449.54 Million | -$654.59 Million | 8.02x | N/A |
| 2023 | $3.59 Billion | $563.95 Million | -$479.45 Million | 6.36x | N/A |
| 2024 | $4.05 Billion | $739.02 Million | -$436.37 Million | 5.48x | N/A |
| 2025 | $13.54 Billion | $982.02 Million | -$416.28 Million | 13.79x | N/A |
Competitor Companies of GH by Market Capitalization
Companies near Guardant Health Inc in the global market cap rankings as of June 17, 2026.
Key companies related to Guardant Health Inc by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #127 globally with a market cap of $177.57 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #182 globally with a market cap of $128.10 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #626 globally with a market cap of $44.18 Billion USD.
- LONZA GROUP UNSP.ADR 1/10 (F:LO3A): Ranked #663 globally with a market cap of $41.04 Billion USD ( €35.10 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #127 | Thermo Fisher Scientific Inc | NYSE:TMO | $177.57 Billion | $472.63 |
| #182 | Danaher Corporation | NYSE:DHR | $128.10 Billion | $181.35 |
| #626 | IDEXX Laboratories Inc | NASDAQ:IDXX | $44.18 Billion | $573.00 |
| #663 | LONZA GROUP UNSP.ADR 1/10 | F:LO3A | $41.04 Billion | €54.50 |
Guardant Health Inc Historical Marketcap From 2018 to 2026
Between 2018 and today, Guardant Health Inc's market cap moved from $4.98 Billion to $ 16.89 Billion, with a yearly change of 19.54%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $16.89 Billion | +24.67% |
| 2025 | $13.54 Billion | +234.34% |
| 2024 | $4.05 Billion | +12.94% |
| 2023 | $3.59 Billion | -0.55% |
| 2022 | $3.61 Billion | -72.81% |
| 2021 | $13.26 Billion | -22.39% |
| 2020 | $17.09 Billion | +64.93% |
| 2019 | $10.36 Billion | +107.87% |
| 2018 | $4.98 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Guardant Health Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $12.69 Billion USD |
| MoneyControl | $12.69 Billion USD |
| MarketWatch | $12.69 Billion USD |
| marketcap.company | $12.69 Billion USD |
| Reuters | $12.69 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Guardant Health Inc
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tu… Read more